异种原始增强疫苗接种驱动 stromal 激活和适应性免疫力对抗 SARS-CoV-2 变种

Ji Hyang Jeon1,2, Seongryong Kim3, Seo-Yeon Kim1

  • 1Division of Infectious Disease Vaccine Research, Center for Vaccine Research, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Republic of Korea.

PubMed
概括

异种疫苗接种 (腺病毒原始,mRNA增强) 增强了对COVID-19变种的免疫反应. 腺病毒启动条件免疫系统,在mRNA疫苗接种时增强T细胞和抗体反应.